US BIOSECURE Act Fuels Indian Pharma Stock Surge; CDMO Market Poised for Growth

• Indian Pharma stocks surged Friday, December 19, with the Nifty Pharma index gaining over 1% after US President Donald Trump signed the FY2026 NDAA, including the US BIOSECURE Act, into law.
• Wockhardt led the gains (+6.5%), followed by Divi's Laboratories, Laurus Labs, Aurobindo Pharma, and Biocon (2-3.5% up). Sai Life and Piramal Pharma also saw gains.
• Brokerage Macquarie predicts the Indian CDMO market, currently $7 billion, could expand to $20 billion by 2030, driven by the BIOSECURE Act.
• Macquarie reiterated an "outperform" rating on CDMO companies, favoring Divi's Laboratories and Syngene, despite an expected 12-24 month lag for new project revenues.
• Sai Life Sciences and Piramal Pharma management corroborated the lag, with Piramal Pharma maintaining flat FY2026 revenue growth guidance but expecting margin expansion.

Why It Matters: US BIOSECURE Act triggers Indian Pharma rally, boosting CDMO growth prospects despite short-term lag.